Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 717

The DOI matches its Crossref record; 103 of the 103 references it cites were found in a registry or an index.

How Do Cytotoxic Lymphocytes Kill Cancer Cells?

Open access
Martínez-Lostao, Luis, Anel, Alberto, Pardo, Julián·2015·Clinical Cancer Research

Abstract

In the past few years, cancer immunotherapy has emerged as a safe and effective alternative for treatment of cancers that do not respond to classical treatments, including those types with high aggressiveness. New immune modulators, such as cytokines, blockers of CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) and PD-1(programmed cell death protein 1)/PD-L1 (programmed death-ligand 1), and interaction or adoptive cell therapy, have been developed and approved to treat solid and hematologic carcinomas. In these scenarios, cytotoxic lymphocytes (CL), mainly cytotoxic T cells (Tc) and natural killer (NK) cells, are ultimately responsible for killing the cancer cells and eradicating the tumor. Extensive studies have been conducted to assess how Tc and NK cells get activated and recognize the cancer cell. In contrast, few studies have focused on the effector molecules used by CLs to kill cancer cells during cancer immunosurveillance and immunotherapy. In this article, the two main pathways involved in CL-mediated tumor cell death, granule exocytosis (perforin and granzymes) and death ligands, are briefly introduced, followed by a critical discussion of the molecules involved in cell death during cancer immunosurveillance and immunotherapy. This discussion also covers unexpected consequences of proinflammatory and survival effects of granzymes and death ligands and recent experimental evidence indicating that perforin and granzymes of CLs can activate nonapoptotic pathways of cell death, overcoming apoptosis defects and chemoresistance. The consequences of apoptosis versus other modalities of cell death for an effective treatment of cancer by modulating the patient immune system are also briefly discussed. Clin Cancer Res; 21(22); 5047–56. ©2015 AACR. See all articles in this CCR Focus section, “Cell Death and Cancer Therapy.”

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-15-0685

Cites

103 of 103 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 103 references

Research works printed but not linked: 5

  1. Antia, 1992, Binding of perforin to membranes is sensitive to lipid spacing and not headgroup, Immunol Lett, 32, 153, 10.1016/0165-2478(92)90108-Z · doi:10.1016/0165-2478(92)90108-z
  2. Davis, 2001, Granzyme A and B-deficient killer lymphocytes are defective in eliciting DNA fragmentation but retain potent in vivo anti-tumor capacity, Eur J Immunol, 31, 39, 10.1002/1521-4141(200101)31:1<39::AID-IMMU39>3.0.CO;2-1 · doi:10.1002/1521-4141(200101)31:1<39::aid-immu39>3.0.co;2-1
  3. Sin, 2012, Intratumoral electroporation of IL-12 cDNA eradicates established melanomas by Trp2(180–188)-specific CD8+ CTLs in a perforin/granzyme-mediated and IFN-gamma-dependent manner: application of Trp2(180–188) peptides, Cancer Immunol Immunother, 61, 1671, 10.1007/s00262-012-1214-8 · doi:10.1007/s00262-012-1214-8
  4. Shanker, 2009, Antigen presented by tumors in vivo determines the nature of CD8+ T-cell cytotoxicity, Cancer Res, 69, 6615, 10.1158/0008-5472.CAN-09-0685 · doi:10.1158/0008-5472.can-09-0685
  5. Pardo, 2009, Caspase-dependent inhibition of mousepox replication by gzmB, PLoS ONE, 4, e7512, 10.1371/journal.pone.0007512 · doi:10.1371/journal.pone.0007512

Cited by

See all 717

Metadata

Authors
Martínez-Lostao, L., Anel, A., & Pardo, J.
Venue
Clinical Cancer Research
Published
2015-11-12
Volume
21
Issue
22
Pages
5047-5056
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2177971463
Cited by
717
References
103
FWCI
8.11
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: How Do Cytotoxic Lymphocytes Kill Cancer Cells? https://app.cochat.ai/papers/10.1158/1078-0432.ccr-15-0685
The paper
Martínez-Lostao, L., Anel, A., & Pardo, J. (2015). How Do Cytotoxic Lymphocytes Kill Cancer Cells? Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-15-0685

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.